Edgewise Therapeutics Sells Muscular Dystrophy Business for $2.65B, Sharpens Cardiovascular Focus
Event summary
- Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65B in July 2026.
- Reported positive top-line data from Phase 2 CIRRUS-HCM trial with EDG-7500 in hypertrophic cardiomyopathy.
- Cash position strengthened to $2.01B post-transaction, excluding taxes and transaction costs.
- Plans to initiate Phase 3 trial for EDG-7500 in Q4 2026 and Phase 2 trial for EDG-15400 in H2 2026.
The big picture
Edgewise Therapeutics' sale of its muscular dystrophy business to Servier marks a strategic pivot towards cardiovascular diseases, aligning with industry trends favoring specialized therapeutic focus. The $2.65B deal significantly bolsters Edgewise's financial position, enabling it to advance high-potential candidates like EDG-7500 and EDG-15400 in a competitive market landscape.
What we're watching
- Pipeline Execution
- Whether Edgewise can successfully initiate and complete Phase 3 trial for EDG-7500 by Q4 2026.
- Financial Flexibility
- How the $2.01B cash position will support cardiovascular pipeline advancement and operational expansion.
- Market Positioning
- The pace at which Edgewise can establish itself as a leading player in the cardiovascular disease space post-transaction.
Related topics